SANOFI US SERVICES INC. for SANOFI US SERVICES INC
What was lobbied
10 issue areas, each in the filer's own words, with who lobbied on it and where.
Animals ANI
Education and awareness of issues related to illegal compounding of veterinary drugs for animals; and issues related to the veterinary biologics National Environmental Policy Act (NEPA) exclusion.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARYANNE DOLBEARE DUNLAP | — |
| PATRICK MAYES MCLAIN | — |
| ANN TAYLOR | — |
Pharmacy PHA
General issues related to the 340B Federal Drug Pricing Program
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SEAN CALLINICOS | — |
| MARYANNE DOLBEARE DUNLAP | — |
| PATRICK MAYES MCLAIN | — |
Trade (domestic/foreign) TRD
General issues related to the Trans-Pacific Partnership (TPP) negotiations.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SEAN CALLINICOS | — |
| PATRICK MAYES MCLAIN | — |
Taxation/Internal Revenue Code TAX
General issues related to corporate tax reform, including the deduction of interest, an extension of bonus depreciation, a delay of the medical device tax, and a strengthened, permanent U.S. R&D tax credit, including all provisions of HR880 "American Research and Competitiveness Act of 2015"; and proposed amendment #2 to the Senate amendment to HR 2029, Rules Committee Print 114-40, showing the text of "Protecting Americans from Tax Hikes Act of 2015"; general issues related to the 40% excise tax on employer-sponsored health care, including all provisions of S2045 and HR2050 "Middle Class Health Benefits Tax Repeal Act", all provisions of HR879 "Ax the Tax on Middle Class Americans' Health Plans Act", and proposed amendment #1 to the Senate amendment to HR2029, Rules Committee Print 114-39, showing the text of the "Consolidated Appropriations Act, 2016"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015".
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARYANNE DOLBEARE DUNLAP | — |
| PATRICK MAYES MCLAIN | — |
| ANN TAYLOR | — |
Copyright/Patent/Trademark CPT
International intellectual property issues; general issues related to patent settlements; and all provisions of HR9 "The Innovation Act" and S1137 "Protecting American Talent and Entrepreneurship Act of 2015".
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SEAN CALLINICOS | — |
| PATRICK MAYES MCLAIN | — |
Economics/Economic Development ECN
General issues related to the importance of foreign direct investment in the U.S.
Foreign entity interest: Sanofi SA, the foreign parent corporation of Sanofi US Services Inc. invests in its business in the U.S.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICK MAYES MCLAIN | — |
| ANN TAYLOR | — |
Health Issues HCR
Education and awareness of the 2015-2016 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all issues related to the Innovations for Healthier Americans Initiative and the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; all provisions of Preserving Access to Orphan Drugs Act (discussion draft), HR3678 "Preserving Access to Orphan Drugs Act" and HR3618 "Orphan Drug Fairness Act"; education and awareness of diabetes and related treatments; education about our new cholesterol lowering drug and policy issues related to cardiovascular disease; issues related to barriers to the export of domestically manufactured vaccines; general issues related to the value of prescription medicines; general issues related to the importation of prescription drugs including all progvisions of S122 "Safe and Affordable Drugs from Canada Act of 2015"; issues related to the Over The Counter (OTC) Monograph reform; and general issues related to access to adult vaccines.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SEAN CALLINICOS | — |
| MARYANNE DOLBEARE DUNLAP | — |
| PATRICK MAYES MCLAIN | — |
| AMY L REDL | — |
| ANN TAYLOR | — |
Medicare/Medicaid MMM
Issues related to the Medicaid prescription drug rebate program policy; general issues related to the Medicare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act".
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SEAN CALLINICOS | — |
| MARYANNE DOLBEARE DUNLAP | — |
| PATRICK MAYES MCLAIN | — |
| AMY L REDL | — |
| ANN TAYLOR | — |
Medical/Disease Research/Clinical Labs MED
General issues related to site infrastructure needs
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SEAN CALLINICOS | — |
| PATRICK MAYES MCLAIN | — |
Torts TOR
General issues related to reforms to the Vaccine Injury Compensation Program (VICP).
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SEAN CALLINICOS | — |
| PATRICK MAYES MCLAIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.